TMC Innovation operates accelerators (TMCi) and the TMC3 collaborative campus on the Texas Medical Center campus, offering access to clinical partners, capital, and shared facilities for MedTech, digital health, and biotech startups. TMC Innovation runs accelerator programs and provides access to the large Texas Medical Center hospital network. Programs connect startups with clinicians, investors and pilot sites. Some programs focus on specific areas such as digital health or biotech.

Why it matters

TMC's clinical density (Methodist, MD Anderson, Memorial Hermann, Texas Children's, Baylor) provides unusually deep KOL and pilot-site access for participating startups.

Common pitfalls

•Over-reliance on TMCi resources without independent verification of regulatory obligations can lead to compliance gaps.
•Confusing access to clinical sites with automatic regulatory approval or exemption is a common pitfall.
•Failure to engage with internal regulatory affairs experts while leveraging TMCi
•s resources can result in misinterpretations of regulatory pathways.
•Assuming that innovation support translates to direct regulatory guidance from TMCi personnel is incorrect, as their primary role is acceleration, not regulatory consulting.

Sources

TMC Innovation · TMC
MedTech Europe · MedTech Europe
RAPS · RAPS

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.